ALPHAMAB ONCOLO.DL-000002 (3NK) - Total Liabilities
Based on the latest financial reports, ALPHAMAB ONCOLO.DL-000002 (3NK) has total liabilities worth €503.95 Million EUR (≈ $589.17 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does ALPHAMAB ONCOLO.DL-000002 generate cash to assess how effectively this company generates cash.
ALPHAMAB ONCOLO.DL-000002 - Total Liabilities Trend (2021–2024)
This chart illustrates how ALPHAMAB ONCOLO.DL-000002's total liabilities have evolved over time, based on quarterly financial data. Check 3NK asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
ALPHAMAB ONCOLO.DL-000002 Competitors by Total Liabilities
The table below lists competitors of ALPHAMAB ONCOLO.DL-000002 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bichamp Cutting Technology Hunan Co Ltd
SHE:002843
|
China | CN¥1.08 Billion |
|
Thungela Resources Limited
JSE:TGA
|
South Africa | ZAC21.61 Billion |
|
Douglas Dynamics Inc
NYSE:PLOW
|
USA | $419.61 Million |
|
Mission Produce Inc
NASDAQ:AVO
|
USA | $363.10 Million |
|
Ningbo Donly Co Ltd
SHE:002164
|
China | CN¥1.10 Billion |
|
Daishin Sec
KO:003540
|
Korea | ₩29.90 Trillion |
|
Nabors Industries Ltd
F:NBI1
|
Germany | €3.35 Billion |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
|
China | CN¥1.10 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down ALPHAMAB ONCOLO.DL-000002's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 3NK market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ALPHAMAB ONCOLO.DL-000002's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ALPHAMAB ONCOLO.DL-000002 (2021–2024)
The table below shows the annual total liabilities of ALPHAMAB ONCOLO.DL-000002 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €409.87 Million ≈ $479.18 Million |
-11.86% |
| 2023-12-31 | €465.00 Million ≈ $543.64 Million |
-16.94% |
| 2022-12-31 | €559.86 Million ≈ $654.53 Million |
-32.94% |
| 2021-12-31 | €834.80 Million ≈ $975.97 Million |
-- |
About ALPHAMAB ONCOLO.DL-000002
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. The company offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors… Read more